We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Sorin Group is enrolling patients in a clinical trial of its Equila neurostimulation device for the treatment of heart failure. The device consists of a small implant that goes under the skin of a patient’s chest and stimulates the vagus nerve via a lead in the neck. The stimulation normalizes an imbalance in the autonomic nervous system that contributes to heart failure, the company said. Read More